Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963243 | 0.88 | NPC1 (0.47) | SOAT1RIPK1HTR2AALDH1A1 | |
| SCHEMBL3963129 | 0.88 | NPC1 (0.47) | SOAT1RIPK1HTR2AALDH1A1 | |
| SCHEMBL4630764 | 0.81 | SOAT1 (0.46) | SOAT1HTR2AKDM4EALDH1A1CYP3A4 | |
| SCHEMBL9154366 | 0.81 | RIPK1 (0.57) | SOAT1RIPK1PPARGPPARAPPARD | |
| SCHEMBL3963598 | 0.74 | PPARA (0.42) | SOAT1PPARGPPARAPPARD | |
| SCHEMBL4961989 | 0.73 | ALDH1A1 (0.50) | SOAT1HTR2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL4001303 | 0.73 | CNR2 (0.64) | — | |
| SCHEMBL24221240 | 0.73 | RIPK1 (0.52) | RIPK1HTR2AKDM4EALDH1A1TSPO | |
| SCHEMBL5543819 | 0.72 | CA12 (0.48) | — | |
| SCHEMBL7609631 | 0.72 | CA12 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351858-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| EP-1517679-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050239806-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-10-27 | — | — | US | disclosed |
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB, R&D HEADQUARTERS, GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2005-10-06 | — | — | US | disclosed |
| US-20050187389-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-08-25 | — | — | US | disclosed |
| US-20050165029-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-07-28 | — | — | US | disclosed |
| US-20050153989-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | AMBIT BIOSCIENCES CORPORATION | 2005-07-14 | — | — | US | disclosed |
| EP-1517679-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000294-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165029-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | SOAT1 2412/4885RIPK1 474/4885HTR2A 4156/4885 |
| US-20050187389-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | SOAT1 2412/4885RIPK1 474/4885HTR2A 4156/4885 |
| US-20050153989-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | SOAT1 2412/4885RIPK1 474/4885HTR2A 4156/4885 |
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | INSR, GPR119, IRS1 | SOAT1 523/4885RIPK1 3413/4885HTR2A 4216/4885 |
| US-20050239806-A1 | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases | PRKDC, PRKCA, PRKACA | SOAT1 2412/4885RIPK1 474/4885HTR2A 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.